| pubmed-article:8341294 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8341294 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8341294 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:8341294 | lifeskim:mentions | umls-concept:C0595267 | lld:lifeskim |
| pubmed-article:8341294 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:8341294 | lifeskim:mentions | umls-concept:C0134032 | lld:lifeskim |
| pubmed-article:8341294 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8341294 | pubmed:dateCreated | 1993-9-2 | lld:pubmed |
| pubmed-article:8341294 | pubmed:abstractText | L-Dopa is metabolized to 3-O-methyldopa (3OMD) by catechol-O-methyltransferase (COMT). This reduces the amount of L-dopa available for entry into brain. We studied the effect of OR-611, a new COMT inhibitor, on plasma and brain 6-[18F]-fluoro-L-dopa (6FD) metabolism in cynomolgus monkeys with positron emission tomography (PET). OR-611 pretreatment substantially reduced plasma 6FD metabolism to 3-O-methylfluorodopa (3OMFD). PET measurements of striatal 6FD concentrations showed an average 2.3-fold increase following OR-611 pretreatment, compared to the same animals in the control state. OR-611 inhibits plasma metabolism of 6FD and increases brain uptake of this L-dopa analog. OR-611 appears to be a promising agent as an adjunct to L-dopa for the treatment of patients with Parkinson's disease. | lld:pubmed |
| pubmed-article:8341294 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8341294 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8341294 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8341294 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:8341294 | pubmed:issn | 0885-3185 | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:CedarbaumJ... | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:GjeddeAA | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:RechesAA | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:EvansAA | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:KuwabaraHH | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:GuttmanMM | lld:pubmed |
| pubmed-article:8341294 | pubmed:author | pubmed-author:LégerGG | lld:pubmed |
| pubmed-article:8341294 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8341294 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:8341294 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8341294 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8341294 | pubmed:pagination | 298-304 | lld:pubmed |
| pubmed-article:8341294 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:meshHeading | pubmed-meshheading:8341294-... | lld:pubmed |
| pubmed-article:8341294 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8341294 | pubmed:articleTitle | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. | lld:pubmed |
| pubmed-article:8341294 | pubmed:affiliation | McConnell Brain Imaging Centre, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. | lld:pubmed |
| pubmed-article:8341294 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8341294 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
